Skip to main content
InMed Pharmaceuticals Inc. (INM)
Nov 6, 2026 - INM was delisted (reason: merged into MTRI)
15.56
+2.35 (17.79%)
Inactive · Last trade price on Nov 6, 2026

InMed Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jul - Jun.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Revenue
---4.64.141.09
Revenue Growth
---11.18%279.61%-
Gross Profit
---1.11.40.54
Operating Income
-10.04-9.9-8.45-8.13-8.38-13.59
Net Income
-13.6-12.99-8.16-7.68-7.95-18.6
Earnings Per Share
-29.93-31.20-83.64-201.43-649.21-
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Cash & Investments
1.132.2310.796.618.966.22
Total Debt
--0.740.960.390.79
Net Cash (Debt)
1.132.2310.055.658.575.43
Net Cash Growth
-87.01%-77.76%77.73%-34.01%57.80%-23.98%
Net Cash Per Share
2.505.37102.94148.33699.66-

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Operating Cash Flow
-7.86-8.64-8.1-6.99-7.28-15.58
Capital Expenditures
----0.01-0.16-0.04
Free Cash Flow
-7.86-8.64-8.1-7-7.45-15.62
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Gross Margin
---23.95%33.93%49.89%
Operating Margin
----176.92%-202.60%-1247.60%
Pretax Margin
----166.79%-191.86%-1707.32%
Profit Margin
----166.94%-192.18%-1707.32%
FCF Margin
----152.14%-180.02%-1434.03%

Valuation
Chart
Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingNov '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
PS Ratio
---0.520.758.85